KAS
TGTX icon

Kemnay Advisory Services’s TG Therapeutics TGTX Stock Holding History

Kemnay Advisory Services’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.5K Sell
1,284
-1,569
-55% -$64.2K 0.01% 220
2026
Q1 		$94.8K Buy
2,853
+1,118
+64% +$33.3K 0.02% 127
2025
Q4 		$51.7K Buy
+1,735
New +$56.7K 0.01% 311

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Kemnay Advisory Services's TGTX Position: Q2 2026 in Review

Kemnay Advisory Services reduced its TG Therapeutics (TGTX) stake by 55% in Q2 2026, selling an estimated $64.2K and leaving 1,284 shares worth $70.5K. The position accounts for 0.01% of the portfolio, ranked #220.

Kemnay Advisory Services first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $94.8K in Q1 2026. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Kemnay Advisory Services held 1,284 shares of TG Therapeutics worth $70.5K as of Q2 2026.
  • Kemnay Advisory Services sold 1,569 TG Therapeutics shares in Q2 2026, an estimated $64.2K.
  • TG Therapeutics made up 0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #220 holding.
  • Kemnay Advisory Services first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Kemnay Advisory Services's TG Therapeutics position peaked at $94.8K in Q1 2026.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.